A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

550

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

June 11, 2027

Study Completion Date

March 19, 2029

Conditions

HIV Infections

Interventions

DRUG

VH4524184

Oral tablet will be administered.

DRUG

Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets

Oral table will be administered.

DRUG

Dolutegravir / Lamivudine (DTG/3TC)

Oral tablets will be administered.